ALEC — Alector, Inc. Stock Price, Chart & AI Report

Negative Nov 26, 2025 • 16:00 UTC GlobeNewswire Inc. • The Schall Law Firm

ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

Alector's Phase 3 clinical trial for latozinemab in frontotemporal dementia failed to meet primary endpoints, causing a 50% stock price drop and triggering a potential shareholder lawsuit.

ALEC clinical trial frontotemporal dementia shareholder lawsuit drug development

Sentiment note

Failed clinical trial for key drug candidate, significant stock price decline, and potential legal action from shareholders indicate substantial negative business impact

Negative Oct 21, 2025 • 22:45 UTC GlobeNewswire Inc. • The Association For Frontotemporal Degeneration

Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic

Biotechnology company Alector announced that its drug latozinemab did not meet safety and efficacy criteria in a Phase 3 clinical trial for treating frontotemporal dementia (FTD) caused by GRN gene variants. Despite increasing progranulin protein levels, the drug did not slow disease progression.

ALEC GSK FTD latozinemab clinical trial progranulin neurodegenerative disease

Sentiment note

Drug failed primary clinical trial endpoints, leading to discontinuation of trial and extension studies

Positive Feb 25, 2025 • 13:00 UTC GlobeNewswire Inc. • N/A

Alector to Participate in Upcoming Healthcare Conferences

Alector, a late-stage clinical biotechnology company, announced that it will participate in upcoming investor conferences, where it will present its therapies for neurodegenerative diseases.

ALEC Alector neurodegenerative diseases investor conferences

Sentiment note

The article highlights Alector's participation in upcoming investor conferences, which suggests the company is actively engaging with the investment community and promoting its therapies for neurodegenerative diseases, indicating a positive outlook.

Positive Jan 13, 2025 • 13:00 UTC GlobeNewswire Inc. • N/A

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Alector, a late-stage clinical biotechnology company, provided an update on its pipeline, including the anticipated topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a granulin gene mutation, and the ongoing PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease. The company also highlighted its preclinical and research pipeline, including programs leveraging its Alector Brain Carrier technology.

ALEC GSK Alector latozinemab AL101/GSK4527226 Alzheimer's disease frontotemporal dementia Parkinson's disease

Sentiment note

The article highlights Alector's progress in its clinical trials, preclinical pipeline, and financial position, indicating the company is well-positioned to continue advancing its programs for neurodegenerative diseases.

Positive Aug 29, 2024 • 11:00 UTC GlobeNewswire Inc. • N/A

Alector to Participate in Upcoming Healthcare Conferences

Alector, a clinical-stage biotechnology company, announced that it will participate in several upcoming investor conferences, including the Morgan Stanley 22nd Annual Global Healthcare Conference, the H.C. Wainwright 26th Annual Global Investment Conference, and the 2024 Cantor Global Healthcare Conference.

ALEC Alector investor conferences biotechnology

Sentiment note

The article highlights Alector's participation in upcoming investor conferences, which suggests the company is actively engaging with the investment community and is likely in a strong position to showcase its progress and future plans.

Positive Jul 28, 2024 • 12:05 UTC GlobeNewswire Inc. • N/A

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of its TREM2 agonist AL002 in early Alzheimer's disease. The trial enrolled a representative population, allowing for testing of the novel TREM2 agonist.

ALEC ABBV Alector AL002 TREM2 Alzheimer's disease clinical trial

Sentiment note

The article presents positive data on Alector's INVOKE-2 clinical trial, indicating that the trial enrolled the intended population and will allow for effective testing of the TREM2 agonist AL002.

Unknown Jun 24, 2024 • 12:48 UTC Zacks Investment Research • Zacks Equity Research

Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

PRTA ALEC

Unknown Jun 10, 2024 • 11:00 UTC GlobeNewswire Inc. • Alector, Inc.

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation

ALEC Calendar of Events

Unknown May 9, 2024 • 11:00 UTC GlobeNewswire Inc. • Alector, Inc.

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

ALEC Calendar of Events Health Conference Calls/ Webcasts

Unknown May 8, 2024 • 22:25 UTC Zacks Investment Research • Zacks Equity Research

Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of 20.83% and 8.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ALEC EQ

Unknown Apr 25, 2024 • 14:02 UTC Zacks Investment Research • Zacks Equity Research

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALEC TSVT

Unknown Feb 28, 2024 • 12:00 UTC GlobeNewswire Inc. • Alector, Inc.

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

ALEC Calendar of Events Conference Calls/ Webcasts